camptothecin has been researched along with Cystadenocarcinoma, Serous in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (62.50) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 1 (12.50) | 24.3611 |
| 2020's | 1 (12.50) | 2.80 |
| Authors | Studies |
|---|---|
| Altwerger, G; Azodi, M; Bellone, S; Bianchi, A; Bonazzoli, E; Buza, N; Feinberg, J; Haines, K; Han, C; Huang, GS; Hui, P; Lopez, S; Manara, P; Manzano, A; Menderes, G; Muller Karger, ME; Perrone, E; Ratner, E; Santin, AD; Schwartz, PE; Silasi, DA; Tymon-Rosario, J; Zammataro, L; Zeybek, B | 1 |
| Kim, DY; Kim, JH; Kim, YM; Kim, YT; Lee, SW; Nam, JH | 1 |
| Bodurka, DC; Gano, J; Gershenson, DM; Kavanagh, JJ; Levenback, C; Wharton, JT; Wolf, JK | 1 |
| Higashide, K; Kikkawa, F; Maeda, O; Misawa, T; Obata, NH; Suganuma, N; Tomoda, Y | 1 |
| Hata, K; Higuchi, M; Kajino, T; Shibata, N | 1 |
| Shimizu, Y | 1 |
| Fujimura, M; Fushiki, H; Hidaka, T; Hori, S; Izumi, R; Yamakawa, Y | 1 |
| Shen, K; Sun, Z; Xu, X | 1 |
1 review(s) available for camptothecin and Cystadenocarcinoma, Serous
| Article | Year |
|---|---|
Individualized chemotherapeutic regimen for each histological subtype of ovarian carcinoma.
Topics: Adenocarcinoma, Mucinous; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carcinoma; Carcinoma, Endometrioid; Carcinoma, Transitional Cell; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Female; Humans; Irinotecan; Mitomycin; Ovarian Neoplasms | 1997 |
1 trial(s) available for camptothecin and Cystadenocarcinoma, Serous
| Article | Year |
|---|---|
Phase II trial of irinotecan in patients with metastatic epithelial ovarian cancer or peritoneal cancer.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Agents, Phytogenic; CA-125 Antigen; Camptothecin; Carcinoma, Papillary; Cystadenocarcinoma, Serous; Disease-Free Survival; Dose-Response Relationship, Drug; Female; Humans; Immunoenzyme Techniques; Infusions, Intravenous; Irinotecan; Middle Aged; Neoplasms, Glandular and Epithelial; Ovarian Neoplasms; Peritoneal Neoplasms | 2003 |
6 other study(ies) available for camptothecin and Cystadenocarcinoma, Serous
| Article | Year |
|---|---|
In vitro and in vivo activity of sacituzumab govitecan, an antibody-drug conjugate targeting trophoblast cell-surface antigen 2 (Trop-2) in uterine serous carcinoma.
Topics: Animals; Antibodies, Monoclonal, Humanized; Antibody-Dependent Cell Cytotoxicity; Antigens, Neoplasm; Camptothecin; Cell Adhesion Molecules; Cell Line, Tumor; Cystadenocarcinoma, Serous; Female; Flow Cytometry; Humans; Immunoconjugates; Immunohistochemistry; Mice; Mice, SCID; Molecular Targeted Therapy; Random Allocation; Tissue Array Analysis; Uterine Neoplasms; Xenograft Model Antitumor Assays | 2020 |
The efficacy and toxicity of belotecan (CKD-602), a camptothericin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer.
Topics: Adenocarcinoma, Clear Cell; Adult; Aged; Antineoplastic Agents, Phytogenic; Camptothecin; Cystadenocarcinoma, Serous; Drug Resistance, Neoplasm; Endometrial Neoplasms; Female; Humans; Middle Aged; Neoplasm Recurrence, Local; Neoplasm Staging; Ovarian Neoplasms; Salvage Therapy; Survival Rate; Topoisomerase I Inhibitors; Treatment Outcome | 2010 |
Establishment and characterization of acquired resistance to platinum anticancer drugs in human ovarian carcinoma cells.
Topics: Camptothecin; Carboplatin; Cisplatin; Cystadenocarcinoma, Serous; Drug Resistance; Drug Resistance, Multiple; Etoposide; Female; Glutathione; Glutathione Transferase; Humans; Ovarian Neoplasms; Tumor Cells, Cultured | 1995 |
[Combination therapy with irinotecan and CBDCA for patients in terminal stage of ovarian carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Carboplatin; Cystadenocarcinoma, Serous; Drug Administration Schedule; Female; Humans; Irinotecan; Leukopenia; Middle Aged; Neoplasm Staging; Ovarian Neoplasms; Thrombocytopenia | 1996 |
[Evaluation of a new anti-cancer drug regimen for surface epithelial-stromal ovarian cancer].
Topics: Adenoma; Animals; Antineoplastic Combined Chemotherapy Protocols; Camptothecin; Cisplatin; Cyclophosphamide; Cystadenocarcinoma, Serous; Doxorubicin; Female; Humans; Irinotecan; Mice; Mice, Inbred BALB C; Mice, Inbred ICR; Mice, Nude; Neoplasm Transplantation; Ovarian Neoplasms; Paclitaxel; Tumor Cells, Cultured | 1998 |
[The effect of hydroxycamptothecin and topotecan to SKOV3 and CAOV3 in vitro].
Topics: Antineoplastic Agents; Antineoplastic Agents, Phytogenic; Apoptosis; Camptothecin; Cell Division; Cystadenocarcinoma, Papillary; Cystadenocarcinoma, Serous; Female; Humans; Ovarian Neoplasms; Topotecan; Tumor Cells, Cultured | 1999 |